NervGen Pharma Corp(NGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.4 | Insider Own | 16.53% | Shs Outstand | 106.4M | Perf Week | 1.41% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | 23.08% | Insider Trans | - | Shs Float | 89.8M | Perf Month | -24.61% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.1 | Inst Own | 11.23% | Short Float | 5.66% | Perf Quarter | -11.11% |
| Income | -0.02B | P/S | - | EPS this Y | -19.11% | Inst Trans | 12.55% | Short Ratio | 10.13 | Perf Half Y | -60.33% |
| Sales | 0.00B | P/B | 4.64 | EPS next 5Y | 5.8% | ROA | -41.42% | Short Interest | 5.09M | Perf YTD | -74.29% |
| Book/sh | 0.31 | P/C | 2.53 | EPS past 3/5Y | -13.03% -10.94% | ROE | -97.3% | 52W High | -77.14% ($6.30) | Perf Year | -45.66% |
| Cash/sh | 0.57 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.66% | 52W Low | 5.11% ($1.37) | Perf 3Y | 2.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 18.13% | Gross Margin | - | Volatility(W/M) | 6.6% 6.29% | Perf 5Y | -38.33% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.07 | EPS Q/Q | -1.2% | Profit Margin | - | RSI (14) | 31.74 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.07 | Sales Q/Q | - | SMA20 | -9.9% ($1.6) | Beta | 0.73 | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -24.13% ($1.9) | Rel Volume | 0.5 | Prev Close | $1.5 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -337.95% - | SMA200 | -49.73% ($2.86) | Avg Volume(3M) | 0.50M | Price | $1.44 |
| IPO | 2019/4/3 | Option/Short | Yes/Yes | Trades | 1643 | Volume | 250,937 | Change | -4% |
🧬 NervGen Pharma is a Canada-based, clinical-stage biotechnology company focused on a mechanism that overcomes the scar tissue barrier that inhibits axonal regeneration at sites of nerve damage. Founded on neuroscience research, the company has been developing therapeutics for neurological disorders with significant unmet needs, such as spinal cord injury, and is currently in the stage of validating expansion into multiple indications, centered on its lead candidate.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
NGEN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -19.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -38.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.2%.
Tap to view numbers
It ranks #325 of 594 in the industry
Based on market cap of $155M.
CUE#324 Cue Biopharma Inc $156M PER - NGEN#325 NervGen Pharma Corp $155M PER - 
MGNX#326 Macrogenics Inc $152M PER - 
STRO#327 Sutro Biopharma Inc $152M PER - 
TARA#328 Protara Therapeutics Inc $149M PER - 
FAQ
What kind of company is NGEN?
NGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NGEN?
The market cap of NGEN is approximately $155M, ranking 4,217 within its sector.
What is the 52-week high and low for NGEN?
NGEN has recorded a 52-week high of $6.30 and a low of $1.37.
